TCGA-XF-AAN0-01A-11R-A42T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 56.43889619
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.290
- KRAS_SIGNALING_DN+0.260
- ESTROGEN_RESPONSE_EARLY+0.240
- KRAS_SIGNALING_UP+0.200
- IL6_JAK_STAT3_SIGNALING+0.180
- INFLAMMATORY_RESPONSE+0.180
- ALLOGRAFT_REJECTION+0.160
- ESTROGEN_RESPONSE_LATE+0.160
- PANCREAS_BETA_CELLS+0.150
- BILE_ACID_METABOLISM+0.140
Top 10 suppressed
- MYC_TARGETS_V1-0.490
- MYC_TARGETS_V2-0.460
- OXIDATIVE_PHOSPHORYLATION-0.440
- DNA_REPAIR-0.350
- UNFOLDED_PROTEIN_RESPONSE-0.350
- ADIPOGENESIS-0.330
- ANGIOGENESIS-0.310
- TGF_BETA_SIGNALING-0.310
- FATTY_ACID_METABOLISM-0.290
- MTORC1_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3384 | Med | Medulloblastoma | 0.854 |
| 2 | MDT-AP-0424 | Med | Medulloblastoma | 0.823 |
| 3 | TCGA-J2-A4AE-01A-21R-A24H-07 | — | cohortA1 | 0.793 |
| 4 | BS_NT9NZYFD | Ganglioglioma | — | 0.793 |
| 5 | SJEPD031111_D1.RNA-Seq | EPN | EPN Tumor | 0.789 |
| 6 | TCGA-4Z-AA7Q-01A-11R-A39I-07 | — | — | 0.788 |
| 7 | BS_NZ71XCG3 | Med | Medulloblastoma | 0.785 |
| 8 | BS_Y7F9E2E9 | low-grade glioma | — | 0.785 |
| 9 | BS_VTJ9ESSV | DNET | — | 0.782 |
| 10 | ee0e68bf-7fa0-4edc-a9df-30a63c2db34a | — | — | 0.782 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.180 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.180 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.160 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.130 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.110 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.080 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.080 | Inavolisib | — uncovered |
| COMPLEMENT | 0.070 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.020 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.020 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.010 | Inavolisib | — uncovered |